MOST SHARED
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- Why Amazon Rules Retail
- Gold Will Collapse Like Oil Did in 2008: Charts
- China Eastern to Complete Shanghai Air Buy by End '09
- Wave of Debt Payments Facing US Government
- JAL Slides to Record Low on Bankruptcy Jitters
- Prepare For Large Decline In Stocks, Next Year?
- Paul: Audit the Fed
- Nielsen Ratings Coming to Video Games
- The Social Media Gaming Threat
- Strong Banks, Weak Credit: Treasury Rethinks TARP
- How Many US Consumers Will Shop this Weekend?
- Tuesday's Heavy Dose of Data to Dictate 'Risk' Behavior
- GE Capital Losses May See Dramatic Fall: JP Morgan
- Obama says Boosting US Jobs is Top Priority
- World's Largest Share Issue Priced at Deep Discount
- Hormel Profit Jumps Despite Declining Sales
- Heinz Profit Falls, Raises Full-Year View
- Playboy to Outsource Most Magazine Operations: Report
- Can Murdoch Help Bing Challenge Google and Shift the Content Equation?
- HP's Mark Hurd
- HP Comes in As Expected; Is It Time to Buy?
- 9 Stocks That Play Rising Water Costs: Strategists
- Weis' Deal Likely Won't Change Big Money Contracts
- Gold Prices Can Double in 3 Years: Portfolio Manager
- Nov. 23: Unusual Volume Leaders
- Help Wanted—Please Run $4 Billion University
- Apple Comes to AT&T's Rescue
BEND, Oregon, November 9, 2009 /PRNewswire via COMTEX/ -- Bend Research Inc., a company with more than 30 years of experience in applying innovative pharmaceutical technologies to help clients solve their most difficult scientific and technical problems, announced today that it has entered into a collaboration with Vertex Pharmaceuticals Incorporated, a global biotechnology company headquartered in Cambridge, MA.
Through this new collaboration, Vertex will utilize Bend's formulation development and manufacturing services for specific projects and clinical trials, with the goals of both enhancing the delivery of Vertex compounds and supporting the progression of certain Vertex product candidates through clinical development.
The collaboration between Bend Research and Vertex is designed to leverage the fundamental scientific capabilities of each company to solve formulation and process-development challenges and to produce commercial drug products that are optimized for therapeutic benefit.
"It's a great opportunity for both companies," Bend Research CEO Rod Ray explained. "We are excited to be working with Vertex. We share their commitment to delivering breakthrough therapies based on cutting-edge science. Having two great teams working side by side is a powerful combination - we look forward to a long and fruitful relationship." Vertex's Executive Vice President of Global Research and Development and Chief Scientific Officer, Peter Mueller, added, "Our collaboration with Bend Research exemplifies Vertex's commitment to the treatment of serious diseases through cutting-edge science and innovative technologies. We believe Bend's technologies and expertise will provide Vertex with important scientific capabilities that will support our drug development efforts." Bend Research is making its multidisciplinary team of scientists and engineers available to companies for solving tough formulation and development problems.
Bend Research prides itself in offering fast, innovative solutions.
Since late 2008, Bend Research has been rapidly expanding its line-up of industrial partners. Customers that have benefitted from Bend Research's proprietary technology and unique formulation expertise include some two dozen major pharmaceutical companies, mid-size pharmas, and biotech companies around the globe.
About Bend Research Inc.
Bend Research has more than 30 years of experience in helping clients solve their most difficult scientific and technical problems. This success is based on the company's ability to develop, advance and commercialize pharmaceutical technologies. The firm develops innovative drug-delivery solutions from a solid base of fundamental understanding. Bend Research provides formulation and dosage-form support, assists in process development and optimization, manufactures clinical trial quantities of drug candidates in its cGMP facility, and advances promising drug candidates from conception through to commercialization.
The company's flexible, client-focused business model and collaborative approach to working with its customers enable long-term alliances with clients focused on value creation.
Bend Research has more than 140 employees based in three state-of-the-art facilities in Bend, Oregon, USA.
About Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small-molecule drugs for serious diseases. The company's strategy is to commercialize products independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is focused on viral diseases, cystic fibrosis, inflammation, autoimmune diseases, cancer, and pain.
Contact: Dana Settell Bend Research Inc.
64550 Research Road Bend, OR 97701 Phone: +1(541)-382-4100 Fax: +1(541)-382-2713 E-mail: settell@bendres.com SOURCE Bend Research Inc.
www.prnewswire.com Copyright (C) 2009 PR Newswire. All rights reserved -0- KEYWORD: United States of America INDUSTRY KEYWORD: MTC
PHA SUBJECT CODE: JVN
PDT
TRI


